ArticleVeterinary research communications2026
Pilot study of the use of ezetimibe in dogs with hyperlipidemia.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the tolerance and efficacy of ezetimibe in reducing cholesterol and/or triglycerides in dogs with hyperlipidemia. Twenty-three dogs with hyperlipidemia were randomly distributed into three groups: group D (n = 7) received low-fat dietary treatment, group E (n = 9) received ezetimibe treatment, and group DE (n = 7) received low-fat dietary treatment associated with ezetimibe. Serum cholesterol, triglycerides and glucose were evaluated before (T0), between 12 and 18 days (T1) and after 30 days (T2) of treatment. The groups that received ezetimibe associated or not with dietary treatment had a significant reduction (p < 0.05) of serum cholesterol by the end of the study, and the group that received only dietary treatment did not show a significant reduction in cholesterolemia. None of the groups presented a significant reduction in triglycerides. The dogs' owners did not report clinical changes with the use of the medication. The results allowed us to conclude that ezetimibe was well tolerated and effective in reducing serum cholesterol in dogs with hyperlipidemia, without adverse effects under the conditions of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.